top of page

HCW 2026: InflaRx designed izicopan from the start with the goal of having a differentiated, best in class profile vs the first marketed C5aR inhibitor. Now more than ever this could be opportune

Sep 15

1 min read

Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been pulled from the market in many geographies and is currently in contention at FDA, and how izicopan was built to be different. Now InflaRx needs to prove this to investors and regulators of this.

https://vimeo.com/1227160575?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

See All

BIO-Europe 2026: Envisagenics is harnessing RNA splicing as its therapeutic approach - which may open up biology to novel targets

BIO-Europe 2026: Atrogi aims to harness beta-2 agonism to increase muscle mass for a whole host of conditions, including muscle loss due to GLP medicines

BIO-Europe: The FDA decision date for Hansa's IgG-inactivating therapy for kidney transplant patients is coming up on December 19th

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more